Fluoroquinolones exhibit differences in their incidence of rare adverse effects

Drugs and Therapy Perspectives

Volumn 7, Issue 10, 1996, Pages 10-13

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; FENBUFEN; FLEROXACIN; LOMEFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; THEOPHYLLINE;

ADVERSE DRUG REACTION; ARTHROPATHY; DISEASE SEVERITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORBIDITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHOTOTOXICITY; PRESCRIPTION; SEIZURE; SHORT SURVEY; SKIN TOXICITY; TENDINITIS;

EID: 0029889357     PISSN: 11720360     EISSN: None     Source Type: Journal    
DOI: 10.2165/00042310-199607100-00004     Document Type: Short Survey

References (13)

1. Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics: past, present and future. Drug Saf 1995 Dec; 13 (6): 343-58
2. Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol 1996; 41: 277-84
3. British National Formulary No. 31. London: The Pharmaceutical Press, 1996 Mar; 257-9
4. 1995 Physicians GenRx. St Louis, Missouri: Mosby-Year Book, Inc., 1995: 1184-8
5. Gogan N, Bayliff CD, Paterson NAM, et al. Clinical consequences of quinolone-theophylline interactions. Can J Hosp Pharm 1995 Dec; 48 (6): 366-9
6. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalised patients: results of a multi-center, randomised, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994; 38: 547-57
7. Marutani K, Matsumoto M, Otabe Y, et al. Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wave-length UV light. Antimicrob Agents Chemother 1993; 37: 2217-33
8. Sparfloxacin: phototoxicity warrants restriction on use in the community. Presc Int 1996 Feb; 5 (21): 6-8
9. Schaad UB, Salam MA, Aujard Y, et al. Use of fluoroquinolones in paediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infec Dis J 1995; 14: 1-9
10. Tendon rupture on fluoroquinolones. Presc Int 1996 Feb; 5 (21): 20
11. Donck JB, Segaert MF, Vanrenterghem YF. Fluoroquinolones and achilles tendinopathy in renal transplant recipients. Transplantation 1994 Sep 27; 58 (6): 736-7
12. Wijnands WJA, Vree TB, van Herwaarden CLA. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol 1986; 22: 677-83
13. Janknegt R. Fluoroquinolones: use of clinical data to aid formulary choice by the system of objective judgement analysis (SOJA) method. PharmacoEconomics 1994 Jul; 6 (1): 15-33